arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Ocugen, Inc.

OCGN
$0.81 ▼ -0.07 (-7.78%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
13 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
86
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Ocugen, Inc. shows strong fundamentals with top-quartile Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap —
Dividend Yield —
Revenue Growth 8.8% ↗
Op. Margin —
ROIC -409.2% ↘
FCF / Share None
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity -2.26
info Valuation on last close. End-of-day price, Nov 5, 2026.

13-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.41M
↑ +8.8% —
Net Income Profit after all expenses
$-67.85M
↓ -25.5% —
FCF / Share Free cash flow per share
$-0.30
↑ +1.3% —
Long-Term Debt Long-term obligations
$27.54M
↑ +0.7% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Financial Health
100
Cash Quality →
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 13 years · 51 quarters